Bleakley Financial Group LLC Makes New Investment in Lantheus Holdings, Inc. $LNTH

Bleakley Financial Group LLC purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, HoldingsChannel reports. The fund purchased 11,583 shares of the medical equipment provider’s stock, valued at approximately $771,000.

A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Lantheus by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after buying an additional 115,338 shares during the period. M&T Bank Corp bought a new position in Lantheus in the fourth quarter worth about $370,950,000. TD Asset Management Inc raised its holdings in shares of Lantheus by 25.0% during the third quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock valued at $40,568,000 after buying an additional 158,358 shares during the last quarter. William Blair Investment Management LLC raised its holdings in Lantheus by 46.7% during the third quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider’s stock worth $29,475,000 after purchasing an additional 183,059 shares in the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Lantheus by 0.6% during the third quarter. Mackenzie Financial Corp now owns 501,593 shares of the medical equipment provider’s stock worth $25,727,000 after purchasing an additional 2,950 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research analyst reports. Citizens Jmp lifted their price objective on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price objective on shares of Lantheus in a research note on Tuesday, March 17th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Trading Down 0.3%

NASDAQ:LNTH opened at $99.30 on Friday. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $103.89. The stock has a market capitalization of $6.47 billion, a price-to-earnings ratio of 23.93 and a beta of -0.08. The firm has a fifty day simple moving average of $85.66 and a two-hundred day simple moving average of $73.33. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same quarter in the previous year, the firm posted $1.53 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts expect that Lantheus Holdings, Inc. will post 4.41 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.